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 Integration of numerical methods and microscale tools for kinetic characterisation.
 Synthetic biology principles for ‘mix and match’ expression of pairs of enzymes.
 Model predictions for the multi-enzymatic syntheses were veriﬁed experimentally.
 Reaction simulations were used to identify key process bottlenecks.
 Optimum conditions for fed-batch bioreactor operation were identiﬁed.
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a b s t r a c t
Advances in synthetic biology are facilitating the de novo design of complex, multi-step enzymatic
conversions for industrial organic synthesis. This work describes the integration of multi-step enzymatic
pathway construction with enzyme kinetics and bioreactor modelling, in order to optimise the synthesis
of chiral amino-alcohols using engineered Escherichia coli transketolases (TK) and the Chromobacterium
violaceum transaminase (TAm). The speciﬁc target products were (2S,3S)-2-aminopentane-1,3-diol (APD)
and (2S,3R)-2-amino-1,3,4-butanetriol (ABT). Kinetic models and parameters for each of the enzymatic
steps were ﬁrst obtained using automated microwell experiments. These identiﬁed the TK-catalysed
conversions as being up to 25 times faster than the subsequent TAm conversions and inhibition of TAm
by the amino-donor used, (S)-()-α-methylbenzylamine (MBA), as limiting the overall conversion
yields. In order to better ‘match’ the relative rates of the two enzymes an E. coli expression system, based
on two compatible plasmids, was constructed to produce both enzymes in a single host. By control of
induction time and temperature it was possible to produce six times more recombinant TAm than TK to
help balance the reaction rates. To overcome MBA inhibition and an unfavourable reaction equilibrium,
fed-batch addition of the amino-donor was introduced as well as the use of isopropylamine as an
alternate amino-donor. Adopting these strategies, and using the kinetic models to optimise feeding
strategies, the one pot syntheses of APD and ABT were successfully scaled-up to preparative scales.
Excellent agreement was found between the kinetic proﬁles and yields predicted and those achieved
experimentally at the larger scale. In this case the integration of these multi-disciplinary approaches
enabled us to achieve up to a 6 fold greater yield using concentrations an order of magnitude higher than
in previous preparative scale batch bioconversions carried out sequentially.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
1. Introduction
With the recent advances in synthetic biology (McArthur and
Fong, 2010), there is increasing interest in the design of multi-step
enzymatic conversions for the synthesis of speciality chemicals
and pharmaceutical intermediates. Irrespective of whether such de
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novo pathways are ultimately applied in vivo (as a whole cell
biocatalyst) or in vitro (as isolated or immobilised enzymes), there
is a need to understand the mechanisms of the enzymes involved
and to model reaction kinetics in order to optimise the overall
conversion yield. This can be particularly challenging when
designing synthetic routes involving engineered enzymes and
when using non-natural reactants as frequently encountered in
industrial syntheses (Meyer et al., 2007). In these cases appro-
priate reaction mechanisms must ﬁrst be established and then
kinetic parameters determined for multiple enzymes and a variety
of potential starting reactants and pathway intermediates.
A particular target for de novo designed multi-step enzymatic
conversions is the synthesis of complex chiral compounds from
simple starting reactants (Roessner and Scott, 1996; Prather and
Martin, 2008; Dalby et al., 2009). Ideally such reactants would be
cheap, achiral and available from renewable sources (Keasling,
2010). Products such as chiral amino-alcohols are of considerable
industrial interest and represent an important target for multi-
step enzymatic syntheses. They are useful building blocks in the
synthesis of a range of optically pure pharmaceuticals such as HIV
protease inhibitors (Kaldor et al., 1997; Kwon and Ko, 2002), active
molecules such as (S)-amphetamine (Rozwadoska, 1993) or broad
spectrum antibiotics like chloramphenicol and thiamphenicol
(Bhaskar, 2004).
Previously we have established a series of automated,
microwell-based methods to inform early stage bioconversion
process design and aid in quantitative prediction of larger scales
process kinetics (Lye et al., 2003; Micheletti and Lye, 2006). We
have also established ‘mix and match’ expression systems to rapidly
trial pairs of enzymes for use in de novo engineered pathways. The
utility of this approach was illustrated for a sequential, two-step
synthesis comprising carbon-carbon bond formation using a trans-
ketolase (TK), followed by a transaminase (TAm) to create chiral
amino-alcohols from achiral substrates (Rios-Solis et al., 2011). In
that work the wild type Escherichia coli TK and the Chomobacterium
violaceum 2025 (CV2025) TAm were selected for the one-pot
synthesis of diastereoisomer (2S,3R)-2-amino-1,3,4-butanetriol
(ABT) (Scheme 1), while the mutant E. coli TK D469E and the
CV2025 TAm were selected for the synthesis of (2S,3S)-2-amino-
pentane-1,3-diol (APD) (Scheme 2). Nevertheless, the kinetic mod-
elling and optimisation of multi-step biocatalytic processes has
been poorly explored, due to the complexities of integrating the
kinetic models for multiple enzymes and the number of kinetic
parameters involved (Xue and Woodley, 2012). Improved modelling
and simulation would enable hypothetical changes to be explored
in silico, speeding up process development and allowing the
evaluation of process control strategies, to ensure stability and the
desired efﬁciency (Sin et al., 2009).
The aim of this work was to establish detailed kinetic models
for each of the individual enzymatic reactions, exploiting our
previously developed experimental methodologies, in order to
optimise the overall conversion yields of ABT and APD (Schemes
1 and 2). Kinetic models for the various TK and TAm bioconver-
sions were ﬁrst obtained from microscale experimental data using
previously established numerical techniques for rapid kinetic
parameter determination (Chen et al., 2009; Rios-Solis et al.,
2013). These combine traditional initial rate experiments, to
identify a solution in the vicinity of the global minimum, with
nonlinear regression methods to determine the exact location of
the solution thus reducing the number of experiments required.
Once established, the kinetic models were validated against
preparative scale (50 mL) bioconversion data before being used
to identify key reaction constraints (Pollard and Woodley, 2007)
and simulate scenarios for optimal bioreactor operation. These
were again veriﬁed experimentally illustrating the importance of
kinetic modelling to underpin the design and optimisation of
multi-enzymatic systems in synthetic biology.
2. Materials and methods
2.1. Materials
Molecular biology enzymes were obtained from New England
Bio-laboratories (NEB, Hitchin, UK). Nutrient broth and nutrient
agar were obtained from Fisher Scientiﬁc (Leicestershire, UK).
Scheme 1. Reaction scheme of the de-novo transketolase (TK)–transaminase (TAm) pathway for the synthesis of chiral amino-alcohol (2S,3R)-2-amino-1,3,4-butanetriol
(ABT), from achiral substrates glycolaldehyde (GA) and hydroxypyruvate (HPA). TK intermediate product L-(þ)-erythrulose (ERY). Amino-donor (S)-()-α-methylbenzy-
lamine (MBA) R¼Ph and R0 ¼Me, isopropylamine (IPA) R¼R0 ¼Me.
Scheme 2. Reaction scheme of the de-novo TK (D469E)-TAm pathway for the synthesis of chiral amino-alcohol (2S,3S)-2-aminopentane-1,3-diol (APD) from achiral
substrates propionaldehyde (PA) and hydroxypyruvate (HPA). TK intermediate product is (3S)-1,3-dihydroxypentan-2-one (PKD). Amino-donor (S)-()-α-methylbenzyla-
mine (MBA) R¼Ph and R0 ¼Me, isopropylamine (IPA) R¼R0 ¼Me.
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Competent E. coli BL21-Gold (DE3) cells were obtained from
Stratagene (Amsterdam, NL). All other reagents were obtained
from Sigma-Aldrich (Gillingham, UK) unless noted otherwise, and
were of the highest purity available.
2.2. Synthesis of substrates and products
HPA was synthesised by reacting bromopyruvic acid with LiOH
following a previously described method (Morris et al., 1996). PKD
was synthesised in a 100 mL scale bioconversion with 300 mM
HPA, 300 mM PA, 9 mM MgCl2, 2.4 mM TPP, pH 7.0 and 30% v/v of
D469E TK lysate (ﬁnal TK concentration of 0.3 mg mL1). The
reaction was stirred for 10 h at room temperature in a sealed ﬂask
and the pH was maintained at 7.0 using a 718 STAT Titrino pH
controller (Metrohm Ion Analysis, Switzerland). The solution was
dried on silica and puriﬁed by column chromatography (ethyl
acetate: hexane, 1:1) to yield PKD as a colourless oil that crystal-
lised on standing. ABT and APD product standards were prepared
in a multi-step chemical synthesis described elsewhere (Ingram
et al., 2007; Smith et al., 2010).
2.3. Plasmids
2.3.1. Transketolase plasmid and mutagenesis
Plasmid pQR412 contained the complete E. coli TK gene, tktA,
with its native promoter and an N-terminal His6-tag. It was
constructed using the expression vector pMMB67HE (8.8 kb),
which has a RSF1010 origin of replication, the tac promoter, the
Lac repressor and codes for resistance to ampicillin (Ingram et al.,
2007). Even though the plasmid contained the inducible tac
promoter, the expression of the E. coli tktA was constitutive
because of the presence of its native promoter. Site direct muta-
genesis on the TK gene was performed using the Quikchange kit
(Stratagene, Amsterdan, NL) following the supplier's instructions.
The primers used for the TK mutagenesis were the following:
D469E: TCGGTCTGGGCGAACAAGGGCCGACTCACCAG
2.3.2. Transaminase plasmid
Plasmid pQR801 contained the complete Chromobacterium
violaceum 2025 TAm gene with a His6-tag (GenBank accession
no. NP_901695). Plasmid pQR801 was constructed using the
expression vector pET29(a)þ (5.3 kb), which contains an inducible
T7 promoter, the Lac repressor and codes for resistance to
kanamycin (Kaulmann et al., 2007).
2.4. Biocatalyst preparation
2.4.1. Shake ﬂask whole cell TK biocatalyst preparation
Competent E. coli BL21-Gold (DE3) cells were transformed with
the plasmid pQR412 using the heat shock technique described by
the supplier (Stratagene, Amsterdam, NL). An overnight culture of
the transformed cells was obtained in a 100 mL shake ﬂask (10 mL
working volume) of LB-glycerol broth (10 g L1 tryptone, 5 g L1
yeast extract, 10 g L1 NaCl and 10 g L1 glycerol) containing
150 mg L1 ampicillin. Growth was performed at 37 1C with orbital
shaking at 250 rpm using an SI 50 orbital shaker (Stuart Scientiﬁc,
Redhill, UK). The total volume of this culture was used to inoculate a
1 L shake ﬂask (100 mL working volume) which was left to grow for
8 h. The cells were then harvested and following the removal of
broth by centrifugation, they were resuspended in 200 mM HEPES
buffer, pH 7.5 and used for whole cell bioconversions.
2.4.2. Shake ﬂask whole cell TAm and TK–TAm biocatalyst
preparation
Transformation of E. coli BL21-Gold (DE3) cells with the
plasmid pQR801 and inoculum preparation were performed in
the same way as the TK biocatalyst, except that 150 mg L1 of
kanamycin was used for the single transformed cells and
50 mg mL1 of both kanamycin and ampicillin were used for the
double transformed strain. After inoculation of a 1 L shake ﬂask
(100 mL working volume), when the OD600 reached a value of 1.5–
2.0, isopropylthiogalactopyranoside (IPTG) was added to ﬁnal
concentration of 0.2 mM. After 4 h induction, the cells were
harvested and following the removal of broth by centrifugation,
they were resuspended in 200 mM HEPES buffer, pH 7.5 and used
for whole cell bioconversions.
2.4.3. 5 L fermentations
Batch fermentations were carried out in a 7.5 L fermenter
(BioFlo 110, New Brunswick, Hertfordshire, UK) with a working
volume of 5 l. The bafﬂed fermenter had an aspect ratio of 1.79:1
and Rushton impellers (di/dt¼0.25). The temperature was mon-
itored by a thermocouple and automatically controlled at 30 or
37 1C via cold water circulation in the external jacket of the
fermenter in addition to a heating jacket. The pH was measured
by an Ingold gel ﬁlled pH probe (Ingold Messtechnik, Urdorf,
Switzerland) and was controlled with the addition of 85% v/v
H3PO4 (acid) and 28% NH4OH v/v (base). DOT was monitored by a
polarographic oxygen electrode (Ingold Messtechnik, Urdorf, Swit-
zerland) and was maintained at 30% using control of the impeller
speed and using gas blending with 100% oxygen when necessary.
A solution of 80% polypropylene glycol was used as antifoam to
control liquid levels using the automated antifoam probe. Ingoing
air was sterilised by passage through a membrane ﬁlter and
dispersed in the vessel at the base of the lower turbine with a
ring sparger at a ﬂow rate of 5 L min1.
The vessel was ﬁlled with 4.5 L LB glycerol media with a
composition as described in Section 2.4.1 and all the probe
calibrations and pre-sterilization procedures were performed
following the manufacturer instructions. The fermenter was then
sterilised as a complete unit in an autoclave at 121 1C for 20 min,
and after the media was cooled down, ﬁlter-sterilised ampicillin
and kanamycin were added to a ﬁnal concentration of 150 mg L1.
The fermenter was then inoculated aseptically with ﬁve 100 mL
shake ﬂasks cultures previously grown overnight. Data was logged
by on-line measurements of DOT, pH, temperature and speed of
the impeller using the BioCommand software (BioFlo 110, New
Brunswick, Hertfordshire, UK) as well as by taking regular optical
density measurements at 600 nm (OD600) using a spectrophot-
ometer (Thermo Spectronic, Cambridge, UK).
2.5. Bioconversion kinetics
2.5.1. Automated microscale experimental platform
Microscale bioconversions were performed in a glass 96-well,
ﬂat-bottomed microtiter plate with individual wells having a
diameter of 7.6 mm and height of 12 mm (Radleys Discovery
Technologies, Essex, UK). The microplate was covered with a
thermo plastic elastomer cap designed to work with automated
equipment (Micronic, Lelystad, Netherlands). All the bioconver-
sions were performed using 300 ml total volume at 30 1C, pH
7.5 unless noted otherwise, and shaking was provided at
400 rpm with a Thermomixer Comfort shaker (shaking diameter
of 6 mm, Eppendorf, Cambridge, UK) operated on the deck of a
Tecan Genesis robotic platform (Tecan, Reading, UK). The concen-
tration of TK cofactors MgCl2 and thiamine pyrophosphate (TPP)
were 9 mM and 2.4 mM respectively for all reactions. The
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concentration of TAm cofactor pyridoxal-5-phosphate (PLP) was
0.2 mM in all cases. Previous studies have shown that initial
incubation with cofactor was necessary to allow the enzymes to
bind to PLP or TPP (Ellis and Davies, 1961; Van Ophem et al., 1998),
therefore the whole cell suspension with the cofactor solutions
were always added ﬁrst in the well and left to incubate for 20 min
at 30 1C, prior to initiation of the reaction with the addition of the
substrate solutions. Aliquots of 20 μl were taken at various time
intervals and quenched with 380 μl of a 0.1% v/v triﬂuoroacetic
acid (TFA) solution. They were then centrifuged for 5 min at
5000 rpm and transferred into an HPLC vial for further analysis.
All experiments were performed in triplicate. The speciﬁc activ-
ities were determined as the amount of PKD, ERY, acetophenone
(AP), APD and ABT formed per unit of time normalised by the
amount of enzyme used in the reaction.
2.5.2. Preparative scale bioconversions
Bioconversions at preparative scale (working volume of 50 mL)
were performed in a 150 mL titration vessel with thermostat
jacket (Metrohm Ion Analysis, Switzerland). Temperature was
maintained at 30 1C using a circulating water bath (Grant Instru-
ments, Cambridge, UK), mixing was achieved using a magnetic
stirrer at 300 rpm, and the pH was maintained at pH 7.5 unless
noted otherwise by the use of an automated addition of 1 M NaOH
using a 718 STAT Titrino pH controller (Metrohm Ion Analysis,
Switzerland). For preparative scale fed batch reactions, a peristaltic
P-1 pump (Pharmacia Fine Chemicals, Uppsala, Sweden) was used
to add the desired substrate solution over time.
2.6. Analytical methods
Biomass concentration was measured as optical density at
600 nm (OD600) using a spectrophotometer (Thermo Spectronic,
Cambridge, UK) and converted to dry cell weight (DCW) using a
calibration curve where 1 OD600¼0.4 gDCW L1. Protein concen-
trations were obtained using Bradford assay and SDS-PAGE as
described previously (Kaulmann et al., 2007). A Dionex HPLC
system (Camberley, UK) with a Bio-Rad Aminex HPX-87H reverse
phase column (3007.8 mm2, Bio-Rad Labs., Richmond, CA, USA),
controlled by Chromeleon client 6.60 software was used for the
separation and analysis of PKD, ERY and HPA. The system com-
prised a GP50 gradient pump, a FAMOS autosampler, an LC30
chromatography column oven and an AD20 UV/vis absorbance
detector and the method used has been described previously
(Chen et al., 2009). To quantify MBA, AP, APD and ABT, an
integrated Dionex Ultimate 3000 HPLC system (Camberley, UK)
with an ACE 5 C18 reverse phase column (150 mm4.6 mm, 5 mm
particle size; Advance Chromatography Technologies, Aberdeen,
UK) controlled by Chromeleon client 6.60 software was employed
and the method has been reported elsewhere (Kaulmann et al.,
2007). To analyse ABT and APD, the samples were derivatized by
addition of an excess of 6-aminoquinolyl-N-hydroxysuccinimidyl
carbamate. The derivatizing reagent was made in house following
a previously described protocol (Cohen and Michaud, 1993), and
the HPLC method used has been described previously (Ingram et
al., 2007). The enantiomeric excess (ee) of the ketodiols was
determined by derivatization via dibenzoylation for satisfactory
peak resolution by chiral HPLC, the method has been described in
more detail elsewhere (Cázares et al., 2010). Examples of the
different HPLC proﬁles have been published previously (Rios-Solis
et al., 2011).
2.7. Nonlinear regresion methods
A programme was developed using Matlabs software (Math-
Works, Natick, MA, USA) in order to automatically perform all the
nonlinear regressions and statistical analyses following the rou-
tines for kinetic parameter estimation as previously described
(Chen et al., 2008; Rios-Solis et al., 2013). All the nonlinear
regressions were performed using the mesh adaptive pattern
search algorithm in Matlabs known as: “The Genetic Algorithm
and Direct Search Toolbox”. This method was previously shown to
be more likely to achieve global optimisation than gradient-based
methods (Chen et al., 2008). All kinetic parameters are reported as
apparent values given that all enzymes are used in the form of
whole cell biocatalysts.
3. Results
3.1. Determination of enzyme kinetic parameters
In our previous work, several enzyme candidates and biocata-
lyst forms were evaluated for their speciﬁc activities, ﬁnal yield
and enantiomeric excess for the synthesis of amino-alcohols (Rios-
Solis et al., 2011). The outcome was the construction of two whole
cell biocatalysts; one comprising the E. coli wild type TK combined
with the CV2025 TAm and the second comprising the mutant TK
D469E combined with the CV2025 TAm for the synthesis of ABT
and APD respectively (Schemes 1 and 2). The kinetic model and
parameters for the TK synthesis of ERY from GA and HPA have
been reported previously (Chen et al., 2009), likewise for the TAm
mediated synthesis of ABT from ERY and MBA (Rios-Solis et al.,
2013). In contrast the kinetic parameters for the TK D469E
mediated synthesis of PKD and the subsequent CV2025 TAm
mediated synthesis of APD were still unknown. Hence these
kinetic parameters were determined here following the proce-
dures described in our previous works (Chen et al., 2008; Rios-
Solis et al., 2013).
3.1.1. TK kinetic models
Transketolase is an enzyme that catalyses carbon-carbon bond
formation by transferring a C2 moiety (1,2-dihydroxyethyl group)
between a ketose sugar and an aldose sugar (Sprenger et al., 1995)
The TK D469E catalysed synthesis of PKD from HPA and PA is an
irreversible reaction due to the release of CO2 as a side product
(Scheme 2). The bioconversion follows a previously elucidated
ping-pong bi–bi mechanism with competitive substrate inhibition,
which requires thiamine pyrophosphate and Mg2þ as cofactors
(Gyamerah and Willetts, 1997; Chen et al., 2008). The full kinetic
model can thus be written as follows:
d PKD½ 
dt
¼ kcatEiTK HPA½  PA½ 
den
den¼ KPA HPA½  1þ
HPA½ 
KiHPA
 
þKHPA PA½  1þ
PA
KiPA
 
þ HPA½  PA½ 
þKHPA
KiPKD
PA½  PKD½  þKHPAKiPA
KiPKD
ð1Þ
where kcat represents the catalytic rate constant, KPA and KHPA are
the Michaelis–Menten constants of PA and HPA, KiPA, KiHPA and
KiPKD are the inhibition constants of PA, HPA and PKD respectively,
and EiTK is the TK enzyme concentration. Note that the same
kinetic model and equation applies for the synthesis of ERY, in
which case the nomenclature for the keto-acceptor PA should be
substituted by GA and product PKD by ERY.
Following the methodology described in our previous work
(Chen et al., 2008), the values of the kinetic parameters were
experimentally determined from microscale experimental data
and are summarised in Table 1. Fig. 1 shows the experimental
Michaelis–Menten plots for the synthesis of PKD, as well as
two progress curves with microscale experimental data and
model predictions. The reliability and adequacy of the kinetic
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determination methodologies used in this work, as well as the
validation of the TK model using GA have been performed else-
where (Sayar et al., 2009a, 2009b). In that work, among the six
kinetic parameters of the TK model, only 3 were found to display a
positive effect on the performance of the reaction (positive
sensitivity), which were the Michaelis–Menten constant for GA
(KGA), inhibition constant for HPA (KiHPA), and the catalytic rate
constant kcat. Excellent agreement was found between the experi-
mental and predicted values (Fig. 1c and d). The apparent kcat for
the synthesis of PKD using TK mutant D469E was found to be
similar to the previously published value using E. coli TK mutant
D469T in lysate form (Chen et al., 2008). Interestingly, both
Michaelis–Menten constants found in this work were half the
value than the ones published for TK D469T. Although non-
hydroxylated aliphatic aldehydes can be accepted by TK, the
activity is typically very low (Cázares et al., 2010; Smith et al.,
2010). The variant TK D469E was engineered to work towards non-
hydroxylated aliphatic aldehydes like PA; the result of a kcat value
of 642 min1 is impressive, although it is still 5 times smaller than
the wild type enzyme using hydroxylated aldehyde GA (Chen et
al., 2009). The inhibition constants were found to be all in the
same order of magnitude (Table 1). The enantiomeric excess of
PKD was determined to be 90%, which was in agreement with
previous works (Cázares et al., 2010, Rios-Solis et al., 2011).
3.1.2. TAm kinetic models
TAm catalyses enzymatic amino group transfer by a ping-pong
bi–bi mechanism and requires the cofactor pyridoxal 50-phosphate
to catalyse the reaction (Bulos and Handler, 1965; Kuramitsu et al.,
1990). The reaction mechanism is composed of two half reactions,
where in the ﬁrst half reaction, the amino-donor binds to the
enzyme and the amino group is transferred to the pyridoxal
50phosphate cofactor, which forms pyridoxamine 5-phosphate
Table 1
Experimentally established values of the apparent kinetic parameters in Eq. (1) for
the E. coli TK D469E mediated synthesis of PKD and the wild type E. coli TK
mediated synthesis of ERY. The values of the parameters for the synthesis of PKD
were determined according to the methodology of Chen et al. (2008) using a whole
biocatalyst at pH 7.5 and 30 1C. The values of the parameters for the synthesis of
ERY were obtained from literature (Chen et al., 2009).
Apparent kinetic parameter Synthesis of PKD
keto-acceptor:
PA
Synthesis of ERY
keto-acceptor:
GA
Rate constant: kcat (min1) 642 2442
Michaelis constant for HPA: KHPA (mM) 5 18
Michaelis constant for keto-acceptor:
KPA or KGA (mM)
47 16
Inhibition constant for HPA: KiHPA
(mM)
87 40
Inhibition constant for keto-acceptor:
KiPA or KiGA (mM)
542 570
Inhibition constant for ketodiol: KiPKD
or KiERY (mM)
887 536
Fig. 1. (a) Microscale kinetic data showing apparent initial rate of PKD synthesis using TK D469E as a function of [PA] while maintaining [HPA] ﬁxed at 30 mM, and (b) as a
function of [HPA] while maintaining [PA] ﬁxed at 100 mM. For the experiments (a) and (b) [TK] concentration was 0.15 mg mL1. Experiments (c) and (d) represent typical
experimental progress curves and model ﬁts using initial concentrations of (c) 10 mM [PA] and [HPA] and 0.1 mg mL1 [TK] and (d) 100 mM [PA] and [HPA] and 0.4 mg mL1
[TK] showing (●) HPA utilisation and (▲) PKD production. Dotted lines show model predictions based on Eq. (1) using the ﬁnal kinetic parameters in Table 1. For all the
experiments TK biocatalyst was used in whole cell form with 2.4 mM [TPP] and 9 mM [Mg2þ] at 30 1C and pH 7.5 in 200 mM HEPES buffer.
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(PMP), and the respective keto product is released. During the
second half reaction, PMP (bounded to TAm) transfers the amino
group to the acceptor substrate and PLP is regenerated, while the
new aminated compound is released (Bulos and Handler, 1965).
It has been reported that in some TAm bioconversions sub-
strate or product can bind an incorrect enzyme-cofactor form,
creating dead end complexes that cannot react further, causing a
potentially strong form of inhibition (Bulos and Handler, 1965;
Shin and Kim, 1998, 2002). For the CV2025 TAm mediated
synthesis of APD, the presence of abortive complexes has not
previously been shown. Therefore, a recently developed routine
was experimentally applied to the TAm mediated synthesis of APD
to elucidate the partially unknown reaction mechanism and the
values of its parameters (Rios-Solis et al., 2013). Substrate inhibition
was found by the formation of the dead end complex E–PMP–MBA,
which was in agreement with the form of inhibition exhibited in
the TAm mediated synthesis of ABT using MBA as amino-donor
(Rios-Solis et al., 2013). The reaction mechanism is shown in Fig. 2
and the corresponding mathematical model is given in the follow-
ing equation
v¼ kfkrEiTAm MBA½  PKD½ ð½AP½APD=KeqÞ
 
den
den¼ krKMBA PKD½  þkrKPKD MBA½ þkr PKD½  MBA½ þ
kfKAP APD½ 
Keq
þkfKAPD AP½ 
Keq
þkf AP½  APD½ 
Keq
þ krKMBA PKD½  APD½ 
KiAPD
þkfKAPD MBA½  AP½ 
KeqKiMBA
ð2Þ
where kf and kr represents the catalytic rate constants for the
forward and reverse reaction respectively, KPKD, KAP, KAPD and KMBA
are the Michaelis–Menten constants of PKD, AP, APD and MBA,
KiAPD and KiMBA are the inhibition constants of APD and MBA
respectively, EiTAm represents the TAm concentration and Keq is
the equilibrium constant. Again, it should be noted that the same
kinetic model applies for the synthesis of ABT, and in the nomen-
clature the amino-acceptor PKD should be substituted by ERY and
product APD by ABT. As for TK, the kinetic parameters were
determined and are summarised in Table 2.
Fig. 3 shows the experimental Michaelis–Menten plots deter-
mined for both the forward and reverse reactions. The ﬁgure also
shows two progress curves comparing microscale experimental
data and model predictions for different initial substrate concen-
trations. Good agreement was again found between the experi-
mental and predicted data (Fig. 3). A more detailed discussion
about the uncertainty and validation of the kinetic parameters has
been performed previously for the TAm mediated synthesis of ABT
(Rios-Solis et al., 2013). In that work, a sensitivity analysis
suggested a crucial bottleneck was the second half reaction of
the ping pong bi–bi mechanism, in part due to the high Michaelis
Menten constant of substrate ERY. The apparent forward catalytic
Fig. 2. Proposed reaction mechanism for the TAm mediated synthesis of APD. Solid
lines represent the basic kinetic model without the formation of abortive com-
plexes. Dashed arrows represent substrate inhibition via formation of dead end
complex E–PMP–MBA. The reaction mechanism was selected based on the
systematic routine described in Rios-Solis et al. (2013).
Table 2
Experimentally established values of the apparent kinetic parameters for Eq. (2) for the synthesis of APD catalysed by a whole cell E. coli biocatalyst containing the CV2025
TAm. The parameters for APD synthesis were obtained experimentally following our previously described methodology and the parameters for ABT synthesis were obtained
from literature (Rios-Solis et al., 2013).
Kinetic parameter Kinetic parameter in terms
of rate constants
Synthesis of APD
Substrate: PKD
Synthesis of ABT
Substrate: ERY
(1) Catalytic rate constants (min1)
Rate constant forward reaction: kf k3k7
k3 þk7
37 95
Rate constant reverse reaction: kr k2k6
k2 þk6
1.9 12
(2) Michaelis–Menten constants (mM)
Michaelis constant for MBA: KMBA k7 ðk2 þk3 Þ
k1 ðk3 þk7 Þ
1.2 0.5
Amino-acceptor Michaelis constant: KERY or KPKD k3 ðk6 þk7 Þ
k5 ðk3 þk7 Þ
20 95
Michaelis constant for AP: KAP k6 ðk2 þk3 Þ
k4 ðk2 þk6 Þ
18 16
Amino-alcohol Michaelis constant: KABT or KAPD k2 ðk6 þk7 Þ
k8 ðk2 þk6 Þ
23 37
(3) Inhibition constants (mM)
Inhibition constant for MBA: KiMBA k2
k1
5.010-3 4.010-3
Amino-acceptor inhibition constant: KiERY or KiPKD k6
k5
0.2 1.0
Inhibition constant for AP: KiAP k3
k4
1.4 1.1
Amino-alcohol inhibition constant: KiABT or KiAPD k7k8
5.3 3.1
Inhibition constant for MBA complex: KiMBAc k9
k10
26 24
(4) Equilibrium constants
Global equilibrium constant: Keq k1k3k5k7
k2k4k6k8
6407 843
Equilibrium constant for the ﬁrst half reaction: K1 k1k3
k2k4
280 275
Equilibrium constant for the second half reaction: K2 k5k7k6k8
22 3.1
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rate constant for the TAm mediated synthesis of PKD was 3-fold
smaller than the one reported for the synthesis of ERY (Rios-Solis
et al., 2013). In contrast, the Michaelis–Menten constant of PKD
was 5 times smaller than the one determined for ABT synthesis,
while the rest of the constants were in the same order of
magnitude (Table 2). Simulations showed that by using the same
enzyme concentration, the conversion rate of ERY by TAm to ABT
would be relatively faster than the one of PKD to APD at
concentrations above 200 mM. Nevertheless, at concentration
below 30 mM, the low Michaelis–Menten constant of PKD com-
pared to ERY would compensate the higher catalytic constant for
ERY, giving comparable reaction rates for both amino-acceptors
(simulation not shown).
3.2. Production of dual TK–TAm biocatalyst for the one-pot syntheses
When performing a multi-step biosynthesis, the choice of using
pure enzymes or whole cells is fundamental to the design of the
process. Using isolated enzymes involves higher upstream costs
while whole-cell processes demands additional downstream costs
(Woodley, 2006). In the case of TAm, it was found to have better
catalytic efﬁciencies in the whole cell form due to increased
enzyme stability (Halim et al., 2014; Rios-Solis et al., 2013).
Although both TK and TAm biocatalysts could be added indepen-
dently, so as to match their kinetic activities, this would double the
cost of biocatalyst production. Furthermore, as progress is made to
include larger numbers of enzymes in designed synthetic path-
ways then the efﬁciency of expression in a single host, with
matched expression levels, will be critical for industrial imple-
mentation. The “mix and match” expression system, ﬁrst proposed
Hussain and Ward (2003), would facilitate the necessary separate
regulation of TK and TAm expression in E. coli being based on two
plasmids with different origins of replication and antibiotic resis-
tance genes (Rios-Solis et al., 2011).
Based on the above results, the kcat of TK was 17 or 25 times
higher than the corresponding TAm kcat values in the de novo
pathways to synthesise APD and ABT respectively (Tables 1 and 2).
The optimum enzyme ratio would also depend on the concentra-
tion of the different substrates used but assuming an equimolar
substrate ratio, due to the reaction stoichiometry, simulations
showed the most effective TAm/TK ratio would be 19 and 12 for
the ABT and APD one pot syntheses respectively.
In this work it was found that by manipulating the fermenta-
tion temperature and induction time, it was possible to modify the
ﬁnal TK and TAm concentration of the enzymes in the whole cell
biocatalyst. Fig. 4 shows the expression proﬁles of TK and TAm
during a 5 L fermentation at 30 and 37 1C with early and late
exponential phase induction of TAm with IPTG (0.1 mM). It was
found that by performing the 5 L fermentation at 37 1C with early
exponential phase induction of TAm, it was possible to achieve a
ﬁnal biomass concentration of 8.570.5 gDCW L1 after 8 h of
fermentation (speciﬁc growth rate of 0.4370.07 h1). The ﬁnal
Fig. 3. (a) Microscale kinetic data showing apparent initial rate of AP formation for the forward reaction as a function of (○) [MBA] while maintaining [PKD] ﬁxed at 100 mM,
and as a function of (Δ) [PKD] while maintaining [MBA] ﬁxed at 10 mM. (b) Apparent initial rate of MBA formation for the TAm reverse reaction as a function of (○) [AP] while
maintaining [APD] ﬁxed at 100 mM, and as a function of (Δ) [APD] while maintaining [AP] ﬁxed at 35 mM. For experiments (a) and (b) [TAm] concentration was
0.3 mg mL1. Experiments (c) and (d) represent typical experimental TAm progress curves and model predictions using an initial concentration of (c) 20 mM [PKD] and
10 mM [MBA] and 0.2 mg mL1 [TAm] and (b) 100 mM [PKD] and 50 mM [MBA] and 0.3 mg mL1 [TAm] following(▲) PKD, (■) MBA and (●) APD. Dotted lines show model
predictions based on Eq. (2) and ﬁnal kinetic parameters in Table 2. For all the experiments TAm biocatalyst was used in whole cell form with 0.2 mM [PLP] at 30 1C and pH
7.5 in 200 mM HEPES buffer.
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TAm and wild type TK concentrations were of 1.770.1 and
0.3170.05 g L1 (Fig. 4a), representing 39% and 7% respectively
of the total cellular protein as determined by SDS PAGE (TAm/TK
ratio of 6). Similar results were obtained for the dual TK D469E
and the CV2025 TAmwhole cell biocatalyst. This enzyme ratio was
2 and 3 times smaller than the optimum value determined for the
synthesis of APD and ABT respectively.
A fermentation performed at 30 1C with early induction
achieved the highest TAm/TK ratio of 9 compared to the value of
6 obtained with the corresponding fermentation at 37 1C.
However, the high ratio at 30 1C was achieved due to a 43%
decrease in TK expression compared to the result at 37 1C. This
was not desirable for the one pot synthesis of amino alcohols,
where a higher TAm/TK ratio is favourable. Overall, not only was
the TK expression higher at 37 1C with early induction, but also the
TAm expression was higher, making the biocatalyst produced at
37 1C with early induction economically more suitable for the
multi-step synthesis of amino alcohols. These two dual TK–TAm
whole cell biocatalysts were subsequently used for one-pot
bioconversions at both microwell and preparative scales.
Fig. 4. Concentration proﬁles of wild type TK (●) and TAm (○) in a 5 L fermentation performed at 37 1C with 0.1 mM IPTG induction in the (a) early and (b) late exponential
growth phase and at 30 1C with induction in the early (c) and (d) late exponential phase. The concentration of each enzyme was calculated assuming that 50% of the total dry
cell biomass of E. coli cells were proteins (Watson, 1972), and by obtaining the percentage of total protein of the corresponding enzyme by SDS-PAGE. Error bars represent
one standard deviation about the mean (n¼3).
Table 3
Comparison of the different bioreactors and reaction conditions used for operation of the multi-step syntheses using the
two dual TK–TAm whole cell E. coli biocatalysts.
Bioconversion scale Microscale Preparative scale
Temperature (1C) 30 30
Mixing device Orbital shaking platform (diameter¼6 mm) Magnetic stirrer
Mixing (rpm) 300 300
Working reaction volume 300 ml 50 mL
Reactor vessel 550 ml micro reactors (96 well glass microplate) 150 glass stirred bioreactor
pH 7.5 7.5
pH control 200 mM HEPES buffer pH-stat using 1 M NaOH (aq)
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3.2.1. Comparison of micro- and preparative scale one-pot
bioconversion kinetics
After the individual kinetic models of all the enzymes were
obtained, the one-pot syntheses of ABT and APD (Schemes 1 and
2) were experimentally performed in 300 ml parallel microwell
bioconversions and in 50 mL working volume preparative scale
bioconversions. This represented a 167-fold scale translation
over which the previously established kinetic models could be
validated. Table 3 compares the different conditions and bioreactor
formats used. The main difference between the two scales of
operation was that the pH of the preparative scale bioconversion
was maintained at 7.5 by the use of automated pH-stat addition of
1 M NaOH in comparison to use of 200 mM HEPES buffer in the
microscale system (Table 3).
3.2.2. Modelling and scale-up of the one-pot synthesis of APD
Previous work has identiﬁed that the TAm amino-donor MBA
could cause a side reaction when bioconversions were operated in
a one-pot mode involving transfer of an amino group to the TK
substrate HPA to yield serine (Rios-Solis et al., 2011). To overcome
this issue, MBA was subsequently added in a single fed-batch
addition after the TK reaction was completed. For the one-pot
synthesis of APD, the ﬁnal whole cell biomass concentration used
was 2.1 gDCW L1, with TAm and TK concentrations of 0.4 and
0.07 mg mL1 respectively. The initial concentration of substrates
PA and HPA were 10 mM, and using Eq. (1) it was predicted that
the TK reaction would reach completion after 7 h, which was the
time when TAm amino-donor MBA was added. A stock solution of
300 mM of the amino-donor was used, therefore the volume
added of the MBA solution represented only 3% of the original
reaction volume, and consequently the dilution of substrates and
products was considered negligible. Fig. 5 shows the experimental
progress curves of the micro and preparative scale multi-step
synthesis of APD. Combining Eqs. (1) and (2), the complete
modelling of the one-pot synthesis was also achieved. The micro-
scale bioconversion kinetics generally show very good agreement
with those from the preparative scale synthesis. A summary of the
experimental kinetics and yields at the different scales and those
from the model predictions is provided in Table 4.
The difference in TK and TAm speciﬁc activities of both scales
were statistically not signiﬁcant (Table 4). This indicates that the
biocatalyst did not lose activity in the scale-up process, and also
that the preparative scale synthesis did not suffer any mass
transfer limitations. Excellent agreement was found between the
predicted speciﬁc activities and the experimental data, which
shows that the mathematical models developed using microscale
data were still valid for preparative scale multi-step syntheses.
After 1500 min of bioconversion, a small difference could be
observed between the predicted and experimental data, which
was higher than the experimental error, especially for the pre-
parative scale synthesis. This discrepancy could also be detected in
the ﬁnal yield (% mol/mol) of the large scale bioconversion which
was 7 and 13% smaller than the predicted and microscale data
respectively. Because the predicted initial speciﬁc activities were
in agreement with the experimental results of both scales
(Table 4), and the discrepancies only appeared after 1500 min of
reaction, the difference in the ﬁnal conversion was attributed to a
decrease in stability of TAm, probably caused by the toxicity of
MBA. Toxicity of the amino-donor towards TAm has also been
reported in other works (Yun et al., 2004; Rios-Solis et al., 2013). In
addition, although APD was a non-natural substrate, consumption
of APD by the whole cells could also contribute to the difference in
yields, as it has previously been shown for similar amino-alcohols
(Ingram et al., 2007). Others who have investigated scale-up of
TAm bioconversion from the ml to mL scale have reported a 30%
difference in the ﬁnal yield (% mol/mol) mainly attributed to pH
ﬂuctuations in the small scale system (Truppo et al., 2009). The use
of 200 mM HEPES here enabled the maintenance of a constant pH
thus helping to improve agreement between the different scales.
3.3. Modelling and scale-up of the one-pot synthesis of ABT
In the same way as for the one-pot synthesis of APD, the one-
pot synthesis of ABT (Scheme 1) was performed at the two scales.
Due to the higher susceptibility of ERY and ABT to be consumed by
side reactions in whole cell systems compared to PKD and APD
(Ingram et al., 2007), 25% less biomass concentration was used.
Therefore the concentration of TK and TAm were 0.05 and
0.3 mg mL1 and the starting concentration of substrates GA and
HPA was 30 mM. Eq. (2) predicted that after 250 min, the TK
bioconversion would reach completion. After this time, MBA was
added to a ﬁnal concentration of 10 mM in the same way as for the
synthesis of APD. An excess of ERY to MBA of 3:1 was maintained
in the bioconversion due to the lower TAm Michaelis–Menten
constant for ERY compared to MBA (Table 2). This was done with
the aim to speed-up the one-pot synthesis and avoids enzyme
Fig. 5. Scale-up and modelling of the whole cell E. coli TK–TAm one-pot synthesis
of APD following: (□) HPA, (○) PKD and (Δ) APD using microscale experimentation
and (■) HPA, (●) PKD and (▲) APD for the preparative scale synthesis. Reaction
conditions: 10 mM [HPA] and [PA], 0.2 mM [PLP], 2.4 mM [TPP], 9 mM [Mg2þ],
30 1C, pH 7.5. 10 mM MBA was added after 420 min. [TK] and [TAm] were 0.07 and
0.4 mg mL1 respectively in whole cell form. Kinetic proﬁles (solid lines) modelled
by combining Eqs. (1) and (2) with the corresponding kinetic parameters from
Tables 1 and 2. Error bars represent one standard deviation about the mean (n¼3).
Table 4
Experimental reaction rates and yields for the one-pot synthesis of APD shown in Fig. 5 based on microscale and preparative scale bioreactor data. The predicted values were
obtained using Eqs. (1) and (2) with the kinetic parameters from Tables 1 and 2 respectively.
Apparent kinetic parameter Microscale data Preparative scale data Model prediction
E. coli D469E TK initial speciﬁc activity (mmol min1 mg1) 1.370.2 1.270.2 1.1
CV2025 TAm initial speciﬁc activity (mmol min1 mg1) 0.170.01 0.170.02 0.12
Final APD yield (% mol/mol) 9376 8576.5 98
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deactivation by MBA, as well as ABT and ERY consumption by the
whole cells.
Fig. 6 shows the complete experimental progress curves of the
micro and preparative scale bioconversions. Combining Eqs.
(1) and (2) with their respective parameters (Tables 1 and 2) again
enabled modelling of the complete conversion proﬁle. Good
agreement was found between the two scales with a maximum
experimental difference in ABT synthesis of 11%, which was not
statistically signiﬁcant. The kinetic results from the different scales
and the model are summarised in Table 5.
For this second bioconversion there was a 25% difference
between the TK experimental and predicted speciﬁc activity
(Table 5). This was probably because the TK kinetic model used
from literature was established at 25 1C and pH 7.0 (Chen et al.,
2009), instead of 30 1C and pH 7.5 as used here. The difference was
considered acceptable however, and good agreement could be
concluded between the predicted and experimental data, validat-
ing the microscale mathematical models for preparative scale
multi-step synthesis. As with the one-pot synthesis of APD, the
ABT yield (% mol/mol) of the preparative scale conversion was 10
and 15% smaller than the microscale and predicted data (Table 5).
Also some consumption of ERY by the whole cell was observed in
both scales (Fig. 6). Nevertheless, by using an excess of 3:1 ERY:
MBA, the reaction time to reach completion was reduced by 3 fold
compared to an equimolar concentration of 10 mM (Eq. (1) and
Table 1). The reduction in time allowed less consumption of ABT
and ERY by the whole cells, as well as less inactivation of TAm
by MBA.
3.4. Selection of optimum reactor operating conditions
3.4.1. One-pot synthesis of ABT with fed-batch addition of MBA
Following validation of the bioconversion models, they were
used to select the best reactor operating conditions to further
increase the bioconversion yields. MBA was found to be inhibitory
to TAm, which is in agreement with previous studies where
problems with TAm were encountered at concentrations greater
than 10 mM (Rios-Solis et al., 2013). This limited the yield of the
TAm bioconversion in equimolar concentrations above 10 mM. A
solution to avoid MBA toxicity and inhibition is to use continuous
fed-batch addition of the amino-donor. The Michaelis–Menten
constant of ERY was found in previous work to be 97 mM in
comparison with the one for MBA of 0.5 mM (Rios-Solis et al.,
2013). These values predicted that the production rate of ABT
would not be severely affected by maintaining an MBA concentra-
tion below 10 mM in the bioconversion.
Consequently, a one-pot synthesis of ABT was performed at
preparative scale with fed-batch addition of MBA. The initial volume
of the bioconversion was 50 mL, and the pH and temperature were
controlled at 7.5 and 30 1C. The initial concentration of HPA and GA
was 100 mM which was 10 fold higher than in Fig. 5. The
concentration of TK and TAm were 0.75 and 0.14 mg mL1 respec-
tively using a whole cell biocatalyst. To model the one-pot synthesis
with fed-batch addition of MBA, Eqs. (1) and (2) were combined
with the following differential equations to model the TAm step:
d MBA½ 
dt
¼ RMBAþ
FeedRateMBAFeed
Vol
 MBA½   FeedRate
Vol
ð3Þ
d½ERY
dt
¼ RERY
ERY½   FeedRate
Vol
ð4Þ
d½ABT
dt
¼ RABT
½ABT  FeedRate
Vol
ð5Þ
dVol
dt
¼ FeedRate ð6Þ
where Ri (mMmin1) is the kinetic reaction rate of each compound
deﬁned by Eq. (2), FeedRate (l min1) is the rate of MBA solution
added, MBAFeed (mM) is the concentration of MBA in the feed and
Vol (l) is the working reaction volume.
Eq. (1) predicted that under the previously mentioned condi-
tions, the TK reaction would reach completion after 180 min, at
this time MBA was fed continuously as a 300 mM solution. A
variable ﬂow rate of the MBA solution that would match the
predicted rate of the consumption of the amino-donor by Eq. (3)
would have been desirable (Sayar et al., 2009a, 2009b), however
this can be difﬁcult to achieve in practice. Several simulations were
thus performed using Eqs. (3)–(6) to identify an appropriate
constant ﬂow rate, which would maximise the reaction rate while
maintaining a concentration of MBAo10 mM for the maximum
possible time. The selected ﬂow rate was 0.31 mL h1, which
combined with a calculated duration of the fed-batch operation
of 53 h, meant that a total of 5 mmol of MBA would be added to
the reaction equivalent to a normalised concentration of 100 mM
for an initial reaction volume of 50 mL.
Table 5
Experimental reaction rates and yields for the one-pot synthesis of ABT shown in Fig. 6 based on microscale and preparative scale bioreactor data. The predicted values were
obtained using Eqs. (1) and (2) with the kinetic parameters from Tables 1 and 2 respectively.
Apparent kinetic parameter Microscale Preparative scale Predicted data
Wild type TK initial speciﬁc activity (mmol min1 mg1) 2.070.2 1.970.2 1.5
CV2025 TAm initial speciﬁc activity (mmol min1 mg1) 0.2170.02 0.1870.02 0.19
Final ABT conversion (% mol/mol) 9479 84711 99
Fig. 6. Scale-up and modelling of the whole cell E. coli TK–TAm one-pot synthesis
of ABT following: (□) HPA, (○) ERY and (Δ) ABT using microscale experimentation,
and (■) HPA, (●) ERY and (▲) ABT for the preparative scale synthesis. Reaction
conditions: 30 mM [HPA] and [PA], 0.2 mM [PLP], 2.4 mM [TPP], 9 mM [Mg2þ],
30 1C, pH 7.5. MBA was added to a concentration of 10 mM after 250 min. [TK] and
[TAm] were 0.05 and 0.3 mg mL1 in whole cell form. Kinetic proﬁles (solid lines)
modelled by combining Eqs. (1) and (2) with the corresponding kinetic parameters
from Tables 1 and 2. Error bars represent one standard deviation about the mean
(n¼3).
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Fig. 7 shows the experimental progress curves and the predicted
normalised concentration for the one-pot synthesis of ABT with fed-
batch MBA addition. In order to compare the performance of the
different MBA addition modes, another one-pot synthesis using a
single shot addition of 5 mmol of S-MBA (carefully added to allow
the system to adjust pH) after 180 min was performed and is also
shown in Fig. 7. Reasonable agreement was found between the
experimental and predicted data for the synthesis with fed-batch
addition of MBA shown in Fig. 7. After 2000 min, the consumption
rate of MBA by TAm became less than the feed rate of MBA,
therefore accumulation of the amino-donor started to occur. No
further conversion was obtained after 3200 min; this was probably
caused due to enzyme deactivation instead of an equilibrium
constraint due to the high equilibrium constant determined for
the bioconversion of 843 (Table 2). In the bioconversionwith a single
shot addition of MBA, as Eq. (2) predicted, the rate of ABT synthesis
was initially faster than for the fed-batch bioconversion, resulting in
higher ABT yields for the ﬁrst 1000 min of reaction. Nevertheless, it
appears TAm was totally inactivated after 1000 min by the higher
concentration of MBA in comparison with the fed-batch bioconver-
sion, and no further production of ABT was measured after that
time. The result was a ﬁnal conversion yield of 62% mol/mol for the
bioconversion with fed-batch addition, which was 25% higher than
the corresponding yield using the one shot addition of MBA.
3.4.2. One-pot synthesis of APD with fed-batch addition of IPA
Although the bioconversions using MBA were determined not
to be equilibrium controlled (Table 2), the bioconversions did
suffer from toxicity and inhibition problems of the amino-donor.
IPA had shown great potential in microscale bioconversions at low
substrate concentrations and was therefore selected as a new
amino-donor (Rios-Solis et al., 2011). In addition, any excess of IPA
added in a fed-batch mode can be easily evaporated due to its high
volatility (Smith et al., 2010).
Due to IPA evaporation using the microscale tools, it was not
possible to obtain reliable data to determine the kinetic
parameters with this substrate, nevertheless because the TAm
reaction mechanism is divided into two half reactions, it was
assumed that the Michaelis Menten constant of ERY and PKD was
still high, and that inhibition and toxicity of the amino donor
would still be present. Therefore, a preparative scale, one-pot
synthesis of APD was performed with fed-batch addition of IPA.
The initial concentration of PA and HPA were 200 mM (20 fold
higher than the concentrations used in Fig. 5). The concentration
of TK D469E and the CV2025 TAm were 0.75 and 0.14 mg mL1
using a whole cell biocatalyst. Using Eq. (1) and the kinetic
parameters from Table 1, it was predicted that the TK reaction
would reach completion after 10 h. At that time, a solution of IPA
500 mM was fed continuously at a ﬂow rate of 0.42 mL h1 during
48 h, so that a total amount of 10 mmol of IPA would be added to
the vessel equivalent to a normalised concentration of 200 mM in
50 mL. Fig. 8 shows the experimental progress curve for normal-
ised concentrations of HPA, PKD and APD, as well as the predicted
data of the TK step (the TAm step was not modelled because the
kinetic parameters using IPA were not determined in this work).
Excellent agreement was found between the experimental and
predicted TK data using Eq. (1), which validated the TK model for
concentrations as high as 200 mM in a preparative scale synthesis.
The TAm bioconversion did not seem to be inhibited by any
accumulation of IPA during the 3000 min that the amino-donor
was fed, suggesting that any excess of IPA evaporated away to
below inhibitory levels. A total volume of IPA solution of 20 mL
was added to the bioreactor, leading to a ﬁnal APD yield of 70%
mol/mol. This yield was 3.5 fold higher than the yield obtained for
similar batch reaction conditions for a single TAm step bioconver-
sion (data not shown). This suggested that fed-batch IPA addition
could be overcoming inhibition or toxic effects on TAm activity at
high concentrations.
Table 6 shows a summary of the different bioreactor conﬁg-
urations, initial concentrations, amino-donor selection and ﬁnal
yields for the different preparative scale one pot syntheses of APD
and ABT. Comparing these results with literature, a previous
TK–TAm two step, preparative scale batch synthesis of APD (using
2 bioreactors) had achieved a ﬁnal product concentration 37.8 mM
from a starting TK substrate concentration of 300 mM (12.6% mol/
Fig. 7. Typical progress curves for modelling the TK–TAm one-pot synthesis of ABT
with continuous fed-batch addition of MBA (reference volume of 50 mL): (■) HPA,
(●) ERY and (▲) ABT, and with a single shot addition of MBA showing (Δ) ABT for
preparative scale bioconversions. Initial reaction conditions: 50 mL working
volume, 100 mM [HPA] and [GA], 0.2 mM [PLP], 2.4 mM [TPP], 9 mM [Mg2þ],
30 1C, pH 7.5, 25 mM HEPES. For the fed-batch addition, a solution of 300 mM
[MBA] was added after 180 min with a constant ﬂow rate of 0.31 mL h1 or 5 mmol
of pure MBA was added in the single shot addition of the amino-donor. [TK] and
[TAm] were 0.14 and 0.75 mg mL1 respectively in whole cell form. Kinetic proﬁles
modelled by combining Eqs. (2)–(6) with the corresponding kinetic parameters
from Tables 1 and 2 for continuous fed-batch (solid lines) and single shot (dashed
line) addition of MBA.
Fig. 8. Typical progress curves for modelling the TK–TAm one-pot synthesis of APD
with continuous fed-batch addition of IPA at preparative scale. Concentrations
normalised to a reference volume of 50 mL: (■) HPA, (●) PKD and (▲) APD. Initial
reaction conditions: 50 mL working volume, 200 mM [HPA] and [PA], 0.2 mM [PLP],
2.4 mM [TPP], 9 mM [Mg2þ], 30 1C, pH 7.5, 25 mM HEPES. After 600 min, a solution
of 500 mM [IPA] was added with a constant ﬂow rate of 0.42 mL h1. [TK] and
[TAm] were 0.75 and 0.14 mg mL1 respectively in whole cell form. Kinetic proﬁles
(dashed lines) of the TK step were modelled using Eq. (1) with the corresponding
kinetic parameters from Table 1.
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mol yield) (Smith et al., 2010). In that work 30% of TK intermediate
(PKD) was lost due to product isolation, while a lower concentra-
tion of TAm substrates had to be used due to inhibition. Those
problems were alleviated in this work where no isolation of TK
intermediates was needed, and concentrations 1 order of magni-
tude higher of TAm substrates could be used due to the selected
reaction conditions and reactor conﬁguration. This allowed a ﬁnal
product concentration of 140 mM to be attained from initial TK
reactant concentrations of 200 mM. This represents a 70% mol/mol
conversion and a 6 fold greater yield than in the previous work.
4. Conclusions
The success of synthetic biology relies in great part in the
characterisation and integration of the individual synthetic compo-
nents. For a non-native, multi-enzymatic synthesis, the kinetic
modelling of the individual steps is crucial to being able to “mix
and match” the best enzymes and determine the best reactor
conﬁguration. This needs to be combined with a ﬁne tuning of
expression system to achieve the required individual enzyme con-
centrations. There are practically no studies where those kinetic
analyses combined with synthetic biology tools were performed for
cascade-type and one-pot catalytic reactions, hence limiting its speed
development and application at the industrial scale. The microscale
tools used here allowed those tasks to be performed with minimum
resources and time, allowing a quantitative prediction of the reaction
kinetics and substantial improvements over previously reported
yields. Due to the advances in synthetic biology, the development
of multi-step, one pot biocatalytic processes will increase and
microscale kinetic modelling approaches as shown in this work will
be crucial to speed technology translation to industrial scale.
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